CHF 110.00
In stock
BVT-0139-C250250 µgCHF 110.00
BVT-0139-M0011 mgCHF 325.00
More Information
Product Details
Synonyms NSC 359079; BRN 4732638
Product Type Chemical


MW 570.4
CAS 93908-02-2
Source/Host Chemicals Isolated from Streptomyces sp.
Purity Chemicals ≥98% (HPLC)
Appearance Yellow solid.
Solubility Soluble in DMSO.
Identity Determined by 1H-NMR.
Declaration Manufactured by BioViotica.
Smiles COC1C(O)C(O)C(OC1CO)N1C2=C3NC4=C(C=CC=C4Cl)C3=C3C(=O)NC(=O)C3=C2C2=C1C(Cl)=CC=C2
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light when in solution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Stock solutions are stable for at least 3 months when stored at -20°C.
After reconstitution, prepare aliquots and store at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Antibiotic. Structurally similar to staurosporine.
  • Selective activity against several cancer cell lines.
  • DNA intercalator, resulting in catalytic inhibition of topoisomerases I.
  • Shows significant antitumor properties in vitro (IC50 = 480 nM against mouse B16 melanoma cells and IC50 = 500 nM against P388 leukemia cells).
  • Does not show any inhibitory activity against protein kinases.
Product References
  1. Production and biological activity of rebeccamycin, a novel antitumor agent: J.A. Bush, et al.; J. Antibiot. (Tokyo) 40, 668 (1987)
  2. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives: Y. Yamashita, at al.; Biochemisty 31, 12069 (1992) 
  3. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin: C. Bailly, et al.; Biochemistry 36, 3917 (1997)
  4. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group: F. Anizon, et al.; J. Med. Chem. 40, 3456 (1997)
  5. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition: C. Bailly, et al.; Chem. Biol. 6, 277 (1999)
  6. Discovery of Antitumor Indolocarbazoles: Rebeccamycin, NSC 655649, and Fluoroindolocarbazoles: B.H. Long, et al.; Curr. Med. Chem. 2, 255 (2002) 
  7. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitor: C. Marminon, et al.; Mol Pharmacol 74, 1620-1629 (2008)
  8. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers: A. Dowlati, et al.; Cancer Chemother Pharmacol 65, 73-78 (2009)
  9. New progress of researches in carbazole compounds: F. Zhang, et al.; Chinese J. Org. Chem. 30, 783 (2010)
  10. Checkpoint Kinase 1 activation enhances intestinal epithelial barrier function via regulation of claudin-5 expression: A. Watari, et al.; PLoS One 11, e0145631/1 (2016)
  11. Rebeccamycin attenuates TNF-a-induced intestinal epithelial barrier dysfunction by inhibiting myosin light chain kinase production: A. Watari, et al.; Cell. Physiol. Biochem. 41, 1924 (2017)
  12. The antitumor antibiotic rebeccamycin-challenges and advanced approaches in production processes: K. Pommerehne, et al.; Appl. Microbiol. Biotechnol. 103, 3627 (2019)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.